Product Image

Niacin-Time 500 mg

Carlson
4.7
★ ★ ★ ★ ★
(117 ratings)
Niacin 500 mg
Product Image
Score79
A long-supply time-release nicotinic acid product for established, supervised use. Its high dose remains unsuitable for routine self-directed nutrition.
How scoring works
Quantity:250 Tablet(s) • (250 servings)
Goals:
Cardiovascular Support
Heart Health

Score 79

A long-supply time-release nicotinic acid product for established, supervised use. Its high dose remains unsuitable for routine self-directed nutrition.
How scoring works
$46.75($0.18 per serving)
iHerb
$ 46.75
Report prices

Analysis

Nicotinic acid is explicitly disclosed, while the time-release positioning defines the intended delivery. The large bottle is practical only for users who already know this form and amount are appropriate.

The serving greatly exceeds ordinary vitamin B3 needs. Slower release may soften the immediate flush, but continued exposure can increase concern about liver tolerance.

Its strongest use is clinician-guided cardiovascular support rather than general wellness or skin nutrition. Buying a longer supply does not reduce the need for monitoring.

Who is it for
  • Established high-dose nicotinic acid users
  • Adults following a monitored cardiovascular plan
  • People wanting a longer time-release supply
Best for
  • Supervised long-term niacin routines
  • Time-release nicotinic acid
  • Lipid-focused use

Pros

  • Explicit nicotinic acid form
  • Time-release delivery
  • Long supply

Cons

  • Not suitable for casual use
  • Requires health monitoring
  • Large bottle is a poor trial size

Warnings

  • Regular time-release nicotinic acid use may affect liver enzymes.
  • The high amount can alter glucose or uric acid, which matters for diabetes or gout.
  • Flushing and dizziness can still occur even with time-release delivery.

Nutrient quality

85 Highest impact

Sustained-release nicotinic acid provides a purposeful cardiovascular niacin form. The amount is meaningful for targeted cardiovascular use.

.

Ingredient transparency

84 Highest impact

All meaningful active amounts are clearly disclosed. The supplied data does not include a complete inactive ingredient list.

.

Customer satisfaction

64 Moderate impact

The aggregate satisfaction measure is strong, but the small evidence base limits confidence. Missing feedback themes leave recurring complaints and purpose fit uncertain.

.

Value for money

79 High impact

The price is reasonable for the formula quality and dose. Each serving provides only moderate cost efficiency.

.
Report analysis

Goals

Cardiovascular Support
Cardiovascular Support
Impact
High effect
B+ Goal FitA- Strength of SupportD+ CoverageA+ Formula Quality
Niacin · 500 mg

Timed-release nicotinic acid provides focused lipid-management support at a substantial amount. The product is narrow by design and does not address vascular tone, rhythm, or cardiac energy.

Clear form and dose disclosure make the active easy to assess. A 500 mg timed-release dose can cause flushing and may affect the liver, glucose, or uric acid, so medical monitoring is prudent.

Study evidence
Niacin Supportive 136 studies
Heart Health
Lipid and Cholesterol Balance
Heart Health
Impact
High effect
B- Goal FitA Strength of SupportD CoverageA Formula Quality

Timed-release nicotinic acid is directly relevant to lipid management and is supplied at a clinically significant amount. Clear form disclosure makes its intended effect easier to judge.

The formula is deliberately narrow and offers no support for other cardiovascular pathways. High-dose timed-release niacin can cause flushing and may increase liver risk, making clinician-guided use important.

Study evidence
Niacin Supportive 105 studies

Ingredients

IngredientAmount per serving
Niacin (Nicotinic Acid)
 500 mg
Gluten Free Adults 18–50 Women
Report overview
Niacin (Nicotinic Acid) · 500 mg OverallScore84
A+ Active Ingredient Quality & BioavailabilityB+ Dose, Safety & Label TransparencyC Value

Nicotinic acid at 500 mg is well aligned with cardiovascular-focused niacin use, and timed release may moderate rapid exposure. The label clearly identifies nicotinic acid, but the supplied data does not show a niacin-flush warning. Value is moderate for the amount and conventional form supplied.

View ingredientView products
Loading alternative details
82 Performance

Sustained-Release Niacin with niaXtend 500 mg

Doctor's Best
<p>Sustained-release nicotinic acid provides a clearly identified cardiovascular-focused amount with controlled delivery. Compared with the original, it provides clearer form disclosure or a more purposeful match for cardiovascular-focused niacin use; however, high-dose niacin can still affect the liver and requires explicit safety guidance.</p>
80 Performance

Niacin (Vitamin B3) 500 mg

Solgar
<p>Clearly identified nicotinic acid provides direct high-dose vitamin B3 coverage with strong cardiovascular alignment. Compared with the original, it provides clearer form disclosure or a more purposeful match for cardiovascular-focused niacin use; however, the amount may cause flushing and can affect the liver, glucose, or blood pressure.</p>
82 Performance

No Flush Niacin (Inositol Hexanicotinate) 800 mg

Life Extension
<p>Clearly named inositol hexanicotinate provides substantial flush-free niacin exposure with economical serving value. Compared with the original, it provides clearer form disclosure or a more purposeful match for cardiovascular-focused niacin use; however, its cardiovascular effects may be less direct and reliable than those of nicotinic acid.</p>
86 Budget

Niacinamide B-3 100 mg

Source Naturals
<p>A clearly identified moderate niacinamide tablet offers simple non-flushing vitamin B3 support with excellent serving economics. Serving cost is lower than the original, but it does not provide nicotinic acid’s lipid-focused effects and complete excipient details are missing.</p>
82 Budget

Niacin 100 mg

Nature's Way
<p>Clearly identified nicotinic acid supplies a modest, inexpensive vitamin B3 serving with direct form transparency. Serving cost is lower than the original, but immediate release can still cause temporary flushing and the dose is not intended for intensive cardiovascular use.</p>
82 Budget

Niacin 100 mg

Bluebonnet
<p>Clearly identified nicotinic acid provides a meaningful low-dose option in a simple long-supply capsule. Serving cost is lower than the original, but noticeable flushing remains possible and people sensitive to liver, glucose, or blood-pressure effects should choose carefully.</p>
80 Value

Niacin 50 mg

Carlson
<p>A clearly named low-dose nicotinic acid tablet provides economical and easy-to-assess vitamin B3 support. Its lower serving cost and clearer active design support practical value compared with the original, although the amount is too low for focused cardiovascular use and can still cause flushing.</p>
85 Value

Niacin 100 mg

Source Naturals
<p>A moderate niacinamide tablet provides clearly identified vitamin B3 without typical nicotinic-acid flushing. Its lower serving cost and clearer active design support practical value compared with the original, although the form is intended for nutritional or skin support rather than lipid-focused effects.</p>
80 Value

No-Flush Niacin (Inositol Hexanicotinate) 500 mg

Solgar
<p>Clearly identified inositol hexanicotinate supports a comfort-focused no-flush approach with good serving value. Its quality-adjusted serving economics and clearer active design support practical value compared with the original, although the form is less direct than nicotinic acid for cardiovascular purposes.</p>
Report alternatives

Sources

Published studies used for the product analysis and the top-ranked studies for each ingredient and goal.

  1. Relationship of lipoproteins to cardiovascular events: the AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes).
    Guyton JR; Slee AE; Anderson T; Fleg JL; Goldberg RB; Kashyap ML; Marcovina SM; Nash SD; O'Brien KD; Weintraub WS; Xu P; Zhao XQ; Boden WE · Journal of the American College of Cardiology · 2013
    Randomized trial3,414 participantsCardiovascular Support forNiacin
  2. Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis.
    D'Andrea E; Hey SP; Ramirez CL; Kesselheim AS · JAMA network open · 2020
    Meta-analysis35,760 participants17 studies pooledCardiovascular Support forNiacin
  3. Supplemental Vitamins and Minerals for Cardiovascular Disease Prevention and Treatment: JACC Focus Seminar.
    Jenkins DJA; Spence JD; Giovannucci EL; Kim YI; Josse RG; Vieth R; Sahye-Pudaruth S; Paquette M; Patel D; Blanco Mejia S; Viguiliouk E; Nishi SK; Kavanagh M; Tsirakis T; Kendall CWC; Pichika SC; Sievenpiper JL · Journal of the American College of Cardiology · 2021
    Meta-analysisCardiovascular Support forNiacin
  4. The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression.
    Lavigne PM; Karas RH · Journal of the American College of Cardiology · 2013
    Meta-analysis9,959 participants11 studies pooledCardiovascular Support forNiacin
  5. Effects of niacin on apo A1 and B levels: a systematic review and meta-analysis of randomised controlled trials.
    Saboori S; Yousefi Rad E; Tammam J; Thondre PS; Coe S · The British journal of nutrition · 2024
    Meta-analysis12 studies pooledCardiovascular Support forNiacin
  6. Effect of lipid-lowering therapies on lipoprotein(a) levels: a comprehensive meta-analysis of randomized controlled trials.
    Xie S; Galimberti F; Olmastroni E; Carugo S; Catapano AL; Casula M; META-LIPID Group · Atherosclerosis · 2025
    Meta-analysis145,314 participants147 studies pooledCardiovascular Support forNiacin
  7. Effectiveness of niacin supplementation for patients with type 2 diabetes: A meta-analysis of randomized controlled trials.
    Xiang D; Zhang Q; Wang YT · Medicine · 2020
    Meta-analysis2,110 participants8 studies pooledCardiovascular Support forNiacin
  8. Niacin improves lipid profile but not endothelial function in patients with coronary artery disease on high dose statin therapy.
    Philpott AC; Hubacek J; Sun YC; Hillard D; Anderson TJ · Atherosclerosis · 2013
    Randomized trial66 participantsCardiovascular Support forNiacin
  9. Effects of HDL-modifiers on cardiovascular outcomes: a meta-analysis of randomized trials.
    Verdoia M; Schaffer A; Suryapranata H; De Luca G · Nutrition, metabolism, and cardiovascular diseases : NMCD · 2015
    Meta-analysis69,515 participants18 studies pooledCardiovascular Support forNiacin
  10. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial.
    Elam MB; Hunninghake DB; Davis KB; Garg R; Johnson C; Egan D; Kostis JB; Sheps DS; Brinton EA · JAMA · 2000
    Randomized trial468 participantsCardiovascular Support forNiacin
  11. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group.
    Guyton JR; Blazing MA; Hagar J; Kashyap ML; Knopp RH; McKenney JM; Nash DT; Nash SD · Archives of internal medicine · 2000
    Randomized trial173 participantsCardiovascular Support forNiacin
  12. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia.
    Knopp RH; Alagona P; Davidson M; Goldberg AC; Kafonek SD; Kashyap M; Sprecher D; Superko HR; Jenkins S; Marcovina S · Metabolism: clinical and experimental · 1998
    Randomized trial223 participantsCardiovascular Support forNiacin
  13. Differential effect of two nicotinic acid preparations on low-density lipoprotein subclass distribution in patients classified as low-density lipoprotein pattern A, B, or I.
    Superko HR; McGovern ME; Raul E; Garrett B · The American journal of cardiology · 2004
    Randomized trial180 participantsHeart Health forNiacin
  14. The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration.
    Villines TC; Stanek EJ; Devine PJ; Turco M; Miller M; Weissman NJ; Griffen L; Taylor AJ · Journal of the American College of Cardiology · 2010
    Randomized trial315 participantsHeart Health forNiacin
  15. The effects of extended-release niacin on carotid intimal media thickness, endothelial function and inflammatory markers in patients with the metabolic syndrome.
    Thoenes M; Oguchi A; Nagamia S; Vaccari CS; Hammoud R; Umpierrez GE; Khan BV · International journal of clinical practice · 2008
    Randomized trial50 participantsHeart Health forNiacin
  16. Effect of niacin therapy on cardiovascular outcomes in patients with coronary artery disease.
    Duggal JK; Singh M; Attri N; Singh PP; Ahmed N; Pahwa S; Molnar J; Singh S; Khosla S; Arora R · Journal of cardiovascular pharmacology and therapeutics · 2010
    Meta-analysis5,137 participants7 studies pooledHeart Health forNiacin
  17. Effect of niacin on endothelial function: a systematic review and meta-analysis of randomized controlled trials.
    Sahebkar A · Vascular medicine (London, England) · 2014
    Meta-analysis441 participants7 studies pooledHeart Health forNiacin